Skip to main content
SpringerLink
Log in

Anti-inflammatory Therapy Progress in Major Adverse Cardiac Events after PCI: Chinese and Western Medicine

  • Review
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Acute coronary syndrome (ACS) is one of the leading causes of death in cardiovascular disease. Percutaneous coronary intervention (PCI) is an important method for the treatment of coronary heart disease (CHD), and it has greatly reduced the mortality of ACS patients since its application. However, a series of new problems may occur after PCI, such as in-stent restenosis, no-reflow phenomenon, in-stent neoatherosclerosis, late stent thrombosis, myocardial ischemia-reperfusion injury, and malignant ventricular arrhythmias, which result in the occurrence of major adverse cardiac events (MACE) that seriously reduce the postoperative benefit for patients. The inflammatory response is a key mechanism of MACE after PCI. Therefore, examining effective anti-inflammatory therapies after PCI in patients with ACS is a current research focus to reduce the incidence of MACE. The pharmacological mechanism and clinical efficacy of routine Western medicine treatment for the anti-inflammatory treatment of CHD have been verified. Many Chinese medicine (CM) preparations have been widely used in the treatment of CHD. Basic and clinical studies showed that effectiveness of the combination of CM and Western medicine treatments in reducing incidence of MACE after PCI was better than Western medicine treatment alone. The current paper reviewed the potential mechanism of the inflammatory response and occurrence of MACE after PCI in patients with ACS and the research progress of combined Chinese and Western medicine treatments in reducing incidence of MACE. The results provide a theoretical basis for further research and clinical treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics—2021 update a report from the American Heart Association. Circulation 2021;143:e254–e743.

    Article  PubMed  Google Scholar 

  2. Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med 2017;376:2053–2064.

    Article  CAS  PubMed  Google Scholar 

  3. Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289–1367.

    Article  PubMed  Google Scholar 

  4. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.

    Article  PubMed  Google Scholar 

  5. Byrne RA, Stone GW, Ormiston J, et al. Coronary balloon angioplasty, stents, and scaffolds. Lancet 2017;390:781–792.

    Article  PubMed  Google Scholar 

  6. Shlofmitz E, Torguson R, Zhang C, et al. Impact of intravascular ultrasound on outcomes following percutaneous coronary intervention for in-stent restenosis (iOPEN-ISR study). Int J Cardiol 2021;340:17–21.

    Article  PubMed  Google Scholar 

  7. Rezkalla SH, Stankowski RV, Hanna J, et al. Management of no-reflow phenomenon in the catheterization laboratory. JACC Cardiovasc Interv 2017;10:215–223.

    Article  PubMed  Google Scholar 

  8. Andreou I, Stone PH, Ikonomidis I, et al. Recurrent atherosclerosis complications as a mechanism for stent failure. Hellenic J Cardiol 2020;61:9–14.

    Article  PubMed  Google Scholar 

  9. Polimeni A, Sorrentino S, Spaccarotella C, et al. Stent thrombosis after percutaneous coronary intervention from bare-metal to the last generation of drug-eluting stents. Cardiol Clin 2020;38:639–647.

    Article  PubMed  Google Scholar 

  10. Rios-Navarro C, Daghbouche-Rubio N, Gavara J, et al. Ischemia-reperfusion injury to coronary arteries: comprehensive microscopic study after reperfused myocardial infarction. Ann Anat-Anat Anz 2021;238:151785.

    Article  Google Scholar 

  11. Kaneko H, Anzai T, Naito K, et al. Role of ischemic preconditioning and inflammatory response in the development of malignant ventricular arrhythmias after reperfused ST-elevation myocardial infarction. J Card Fail 2009;15:775–781.

    Article  PubMed  Google Scholar 

  12. Konijnenberg LSF, Damman P, Duncker DJ, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovasc Res 2020;116:787–805.

    Article  CAS  PubMed  Google Scholar 

  13. Ajala ON, Everett BM. Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep 2020;22:66.

    Article  CAS  PubMed  Google Scholar 

  14. Shi DZ. Innovation and development of Academician Chen Ke-ji’s methodology of disease-syndrome combination in the treatment of coronary heart disease. Chin J Integr Tradit West Med (Chin) 2011;31:1017–1020.

    Google Scholar 

  15. Liu SY, Yu DJ. Clinical experience of Weng Weiliang in the treatment of coronary heart disease after stent implantation. Liaoning J Tradit Chin Med (Chin) 2015;42:2098–2099.

    Google Scholar 

  16. Meng W, Wang YH, Guo WQ. Professor GUO Wei-qin’s experience on restenosis after coronary stent. Modern Chin Clin Med (Chin) 2016;23:21–23.

    Google Scholar 

  17. Zhang B, Yao R, Hu C, et al. Epigallocatechin gallate mediated sandwich-like coating for mimicking endothelium with sustained therapeutic nitric oxide generation and heparin release. Biomaterials 2021;269:120418.

    Article  CAS  PubMed  Google Scholar 

  18. Wang CX, Jia S. Advances in the mechanism of restenosis after percutaneous coronary intervention J Xi’an Jiaotong Univ (Med Sci, Chin) 2018;39:303–309.

    Google Scholar 

  19. Niccoli G, Montone RA, Ferrante G, et al. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010;56:1783–1793.

    Article  PubMed  Google Scholar 

  20. Butler MJ, Chan W, Taylor AJ, et al. Management of the no-reflow phenomenon. Pharmacol Ther 2011;132:72–85.

    Article  CAS  PubMed  Google Scholar 

  21. Reffelmann T, Kloner RA. The “no-reflow” phenomenon: basic science and clinical correlates. Heart (British Cardiac Society) 2002;87:162–168.

    Article  PubMed  Google Scholar 

  22. Durante A, Camici PG. Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol 2015;187:273–280.

    Article  PubMed  Google Scholar 

  23. Machado GP, Araujo GNd, Carpes CK, et al. Comparison of neutrophil-to-lymphocyte ratio and mean platelet volume in the prediction of adverse events after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Atherosclerosis 2018;274:212–217.

    Article  CAS  PubMed  Google Scholar 

  24. Romero ME, Yahagi K, Kolodgie FD, et al. Neoatherosclerosis from a pathologist’s point of view. Arterioscler Thromb Vasc Biol 2015;35:e43–e49.

    Article  CAS  PubMed  Google Scholar 

  25. Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J 2015;36:2147–2159.

    Article  PubMed  Google Scholar 

  26. Joner M, Koppara T, Byrne RA, et al. Neoatherosclerosis in patients with coronary stent thrombosis: findings from optical coherence tomography imaging (A report of the PRESTIGE Consortium). JACC Cardiovasc Interv 2018;11:1340–1350.

    Article  PubMed  Google Scholar 

  27. Soehnlein O, Libby P. Targeting inflammation in atherosclerosis—from experimental insights to the clinic. Nat Rev Drug Discov 2021;20:589–610.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Park SJ, Kang SJ, Virmani R, et al. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol 2012;59:2051–2057.

    Article  PubMed  Google Scholar 

  29. Frohlich GM, Meier P, White SK, et al. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013;34:1714–22.

    Article  PubMed  Google Scholar 

  30. Fan Q, Tao R, Zhang H, et al. Dectin-1 contributes to myocardial ischemia/reperfusion injury by regulating macrophage polarization and neutrophil infiltration. Circulation 2019;139:663–678.

    Article  CAS  PubMed  Google Scholar 

  31. Tunon J, Badimon L, Bochaton-Piallat ML, et al. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res 2019;115:10–19.

    Article  CAS  PubMed  Google Scholar 

  32. Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427–431.

    Article  CAS  PubMed  Google Scholar 

  33. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959–1965.

    Article  CAS  PubMed  Google Scholar 

  34. Suades R, Padró T, Alonso R, et al. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thromb Haemost 2013;110:366–377.

    Article  CAS  PubMed  Google Scholar 

  35. Tie C, Gao K, Zhang N, et al. Ezetimibe attenuates atherosclerosis associated with lipid reduction and inflammation inhibition. PLoS One 2015;10:e0142430.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Muller KA, Chatterjee M, Rath D, et al. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. Thromb Haemost 2015;114:498–518.

    Article  PubMed  Google Scholar 

  37. Thomas MR, Storey RF. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost 2015;114:490–497.

    Article  PubMed  Google Scholar 

  38. Wang XL, Deng HF, Li T, et al. Clopidogrel reduces lipopolysaccharide-induced inflammation and neutrophilplatelet aggregates in an experimental endotoxemic model. J Biochem Mol Toxicol 2019;33:e22279.

    Article  PubMed  Google Scholar 

  39. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179–1189.

    Article  CAS  PubMed  Google Scholar 

  40. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–1717.

    Article  CAS  PubMed  Google Scholar 

  41. Ranjbar R, Shafiee M, Hesari A, et al. The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases. J Cell Physiol 2019;234:2277–2295.

    Article  CAS  PubMed  Google Scholar 

  42. Expert Committee of Interventional Cardiology of China Association of Chinese Medicine. Consensus of TCM experts in diagnosis and treatment of chest pain after percutaneous coronary intervention (PCI). J Tradit Chin Med (Chin) 2014;55:1167–1170.

    Google Scholar 

  43. Cheng B, Li XY, Liu KQ, et al. Suggestions of Chinese experts on clinical application of Compound Danshen Dropping Pills. Chin J Integr Tradit West Med (Chin) 2017;37:17–22.

    Google Scholar 

  44. Li C, Li Q, Xu J, et al. The efficacy and safety of Compound Danshen Dripping Pill combined with percutaneous coronary intervention for coronary heart disease. Evid Based Complement Alternat Med 2020;2020:5067137.

    Article  PubMed  PubMed Central  Google Scholar 

  45. A X, Li Z, Luo W, et al. Long-term Compound Danshen Dripping Pills therapy reduces the no-reflow phenomenon in nondiabetes mellitus patients after primary percutaneous coronary intervention for acute myocardial infarction. Ann Palliat Med 2020;9:1144–1151.

    Article  PubMed  Google Scholar 

  46. Shi FL. Effects of Compound Danshen Dripping Pills on serum inflammatory factors and ventricular remodeling in patients with acute myocardial infarction. Chin J Geriatric Care (Chin) 2019;17:74–76.

    Google Scholar 

  47. Pan JL, Jia GJ, Wang M. Effect of Compound Danshen Dropping Pill on the inflammatory response mediated by NF-κB p65 in patients with acute myocardial infarction. Pharm Biotechnol (Chin) 2017;24:120–123.

    Google Scholar 

  48. Cui ZT, Wei WL, Yao JM, et al. Research progress on the protective effect of Qishen Yiqi Dropping Pill on ischemic cardiomyocytes. Clin J Med Officers (Chin) 2015;43:74–77, 94.

    CAS  Google Scholar 

  49. Chen JR, Wei J, Zhu LJ, et al. Progress of pharmacologilal effects on cardiovascular system diseases of Qishen yiqi Dripping Pills. Lishizhen Med Mater Med Res (Chin) 2015;26:434–437.

    Google Scholar 

  50. Yang Q, Cao YS. Study on mechanisms and myocardial protective effect of Qishen Yiqi Dropping Pills on rats with myocardial infarction. Chin Critic Care Med (Chin) 2017;29:501–505.

    Google Scholar 

  51. Cheng L, Meng GTY, Liang JG. Myocardial protection effect of Qishen Yiqi Dropping Pills on patients after PCI and control effect and mechanism on cardiac adverse events. Chin J Exp Tradit Med Form (Chin) 2019;25:78–84.

    Google Scholar 

  52. Jing QQ, Yao L. Effects of Qishen Yiqi Droplet on the early stage of PCI postoperative inflammatory cytokines. J Hubei Univ Chin Med (Chin) 2016;18:38–40.

    Google Scholar 

  53. Liu Q, Lv C, Zhang WD, et al. Advance in modern studies on Shexiang Baoxin Pill. Chin Tradit Herbal Drugs (Chin) 2016;47:1409–1417.

    CAS  Google Scholar 

  54. Fan WH, Wu ZG, Shi HM. Chinese experts’ consensus on Shexiang Baoxin Pill in the treatment of coronary heart disease and angina pectoris. Chin J Integr Tradit West Med (Chin) 2018;38:145–153.

    Google Scholar 

  55. Chen ZH, Ma L. Effects of Shexiang Baoxin Pill on inflammation indicators, cardiac and vascular endothelial function in patients with acute myocardial infarction. J Chongqing Med Univ (Chin) 2013;38:912–914.

    CAS  Google Scholar 

  56. Huang YX, Fang KF, Zhang YH, et al. Effects of Shexiang Baoxin Pills on TCM symptoms and in-stent restenosis in the patients with acute myocardial infarction after PCI. World J Integr Tradit West Med (Chin) 2019;14:227–231.

    Google Scholar 

  57. Feng HL. Effect of Shexiang Baoxin Pill on inflammatory factors and incidence of MACE in patients with angina pectoris after PCI. Chin J Integr Med Cardio-Cerebrovasc Dis (Chin) 2018;16:3698–3700.

    Google Scholar 

  58. Mao C, Fu XH, Yuan JQ, et al. Tongxinluo Capsule for patients with coronary heart disease after percutaneous coronary intervention. Cochrane Database Syst Rev 2015;CD010237.

  59. Li M, Li C, Chen S, et al. Potential effectiveness of Chinese patent medicine for secondary prevention after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2018;9:830.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Huang YT. Effects of Tongxinluo Capsule combined with tirofiban on in-stent thrombosis and inflammatory factors in patients with acute myocardial infarction after PCI. Modern J Integr Tradit Chin West Med (Chin) 2017;26:1805–1807.

    Google Scholar 

  61. Geng HQ, Xie YM, Wang ZF. Clinical comprehensive evaluation of Naoxintong Capsules in treatment of cerebral infarction with qi deficiency and blood stasis syndrome and coronary heart disease angina pectoris. China J Chin Mater Med (Chin) 2021;46:6087–6095.

    Google Scholar 

  62. Ma KH. Buchang Naoxintong Capsule on blood lipid level in acute coronary syndrome and hypersensitive C-reactive protein. World Chin Med (Chin) 2013;8:1442–1444.

    CAS  Google Scholar 

  63. Feng WW, Xiong B, Sun LJ. Effect of Naoxintong Capsule on endothelial function in patients with coronary heart disease after PCI operation. Chin J Exp Tradit Med Form (Chin) 2014;20:225–228.

    Google Scholar 

  64. Wang A, Wang CD. Effect of Naoxintong Capsule on the myocardial perfusion and platelet activation function in patients with acute myocardial infarction after PCI. China Pharm (Chin) 2016;27:3800–3802.

    Google Scholar 

  65. Chen YY, Li H, Wu P, et al. Research progress on pharmacological mechanism of Danhong Injection in treatment of cardiovascular and cerebrovascular diseases. Chin J Exp Tradit Med Formul (Chin) 2021;27:188–196.

    Google Scholar 

  66. Fu CG, Liu LT, Wang YF, et al. Chinese experts consensus on application of Danhong Injection. Chin J Integr Tradit West Med (Chin) 2018;38:389–397.

    Google Scholar 

  67. Jiang X, Lv B, Li P, et al. Bioactivity-integrated UPLC/Q-TOF-MS of Danhong Injection to identify NF-κB inhibitors and anti-inflammatory targets based on endothelial cell culture and network pharmacology. J Ethnopharmacol 2015;174:270–276.

    Article  CAS  PubMed  Google Scholar 

  68. Yang XY, Xing YW, Shang HC. Danhong Injection on inflammatory factors after percutaneous coronary intervention in patients with coronary heart disease: a meta-analysis. Modern Tradit Chin Med Mater Med-World Sci Technol (Chin) 2018;20:2134–2140.

    Google Scholar 

  69. Guo JF, Wu SB, Yang JP, et al.Treatment of Danhong Injection with atorvastatin on endothelial function and inflammation factors in patients with acute coronary syndrome after percutaneous coronary intervention. Chin J Exp Tradit Med Form (Chin) 2015;21:154–157.

    Google Scholar 

  70. Zhang T, Chen H, Huang JS, et al. Effect of Danhong Injection on adverse cardiac events after percutaneous coronary intervention. Chin J Exp Tradit Med Form (Chin) 2018;24:186–191.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Graduate School of Beijing University of Chinese Medicine, Beijing, 100029, China

    Xue-yu Ren, Ying-fei Li, Hui-qing Liu & Hui Lin

  2. Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China

    Qian Lin

  3. Department of Cardiology, Dong Fang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China

    Yang Wu, Jie Wan, Jin-jin Lu, Jing Liu & Xiao-yun Cui

Authors
  1. Xue-yu Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying-fei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui-qing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qian Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jie Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jin-jin Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiao-yun Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All of the authors participated in the generation of the idea. Ren XY wrote the initial version of the manuscript. Li YF, Liu HQ, and Lin H searched the literature; Wan J, Lu JJ, and Liu J proofread and revised the manuscript; Lin Q, Wu Y, and Cui XY revised the manuscript critically. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Xiao-yun Cui.

Additional information

Conflict of Interest

The authors declare no conflicts of interest.

Supported by the Applied Technology Research and Development and Demonstration Projects of Beijing Province (No. Z191100006619071)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ren, Xy., Li, Yf., Liu, Hq. et al. Anti-inflammatory Therapy Progress in Major Adverse Cardiac Events after PCI: Chinese and Western Medicine. Chin. J. Integr. Med. 29, 655–664 (2023). https://doi.org/10.1007/s11655-023-3638-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-023-3638-8

Keywords

Search

Navigation